Home・Stock List・Vaxcyte Inc

Vaxcyte Inc

Open

SectorHealthcare

58.03 -1.01

Buy Sell

Overview

Share price change

24h

Current

Min

56.95

Max

60.14

Key metrics
By Trading Economics
Income	-284M -605M
EPS	-1.97
Employees	507
EBITDA	22M -292M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+94.24% upside

Dividends
By Acuity
Next Earnings	2 Nov 2026

Market Stats
By TradingEconomics
Market Cap	944M 8.7B
Previous open	59.04
Previous close	58.03

News Sentiment

By Acuity

50%

171 / 340 Healthcare

Vaxcyte Inc Chart

Past performance is not a reliable indicator of future results.

Related News

12 Aug 2026, 19:46 UTC

Vaxcyte Inc shares are higher today, supported by broader market gains following positive sentiment from the recent inflation report. The stock remains above its 20-day moving average.

11 Aug 2026, 23:11 UTC

Vaxcyte Inc shares are higher in after-market trading, reflecting positive momentum despite no specific news driving the price action.

10 Aug 2026, 19:56 UTC

Vaxcyte Inc shares are higher, continuing gains since Friday's close, reaching a peak earlier in the session. No specific news was identified for the move.

7 Aug 2026, 21:01 UTC

Vaxcyte Inc shares are lower in after-market hours, continuing a weak trading session without any specific news to explain the decline.

6 Aug 2026, 20:03 UTC

News

Vaxcyte reports a net loss of $284.3 million for Q2. Shares are trading higher as the company anticipates key Phase 3 trial data in 2027.

5 Aug 2026, 19:16 UTC

Vaxcyte Inc. shares are higher today, aligning with broader market trends, despite no specific news identified. The stock remains near its one-month range low.

4 Aug 2026, 20:21 UTC

Vaxcyte Inc. shares are lower in after-market trading, remaining flat since Tuesday's close and positioned below its 20-day moving average.

3 Aug 2026, 19:46 UTC

Vaxcyte Inc's shares are lower today, continuing a decline since Friday. The stock is trading near the lower end of its one-month range.

31 Jul 2026, 19:56 UTC

Correlated Moves

Shares lower amid broader sector sentiment; SPDR S&P Biotech ETF declines.

30 Jul 2026, 18:52 UTC

Vaxcyte Inc's shares are higher today amid strong buying activity, reaching an intraday high but remain below the 20-day moving average.

29 Jul 2026, 18:23 UTC

Vaxcyte Inc is lower in Wednesday's session, breaking a trend of higher daily closes. No specific news was identified to explain the decline.

28 Jul 2026, 18:46 UTC

Vaxcyte Inc. shares are trading lower amid broader market trends and volatility, remaining below the 20-day moving average as bond yields decline.

27 Jul 2026, 19:46 UTC

Vaxcyte Inc shares are trading higher today, despite earlier declines and without specific company news. Broader market volatility is influenced by falling crude oil prices.

23 Jul 2026, 19:16 UTC

Vaxcyte Inc shares are lower today amid a broader decline in tech stocks following earnings reports from Alphabet and Tesla. No specific news was identified.

21 Jul 2026, 18:26 UTC

Vaxcyte Inc is trading higher today, continuing its advance since Monday's close. This movement occurs despite concerns over rising treasury yields and geopolitical tensions.

Peer Comparison

Price change

Vaxcyte Inc Forecast

Price Target

By TipRanks

94.24% upside

12 Months Forecast

Average 114.33 USD 94.24%

High 163 USD

Low 75 USD

Based on 7 Wall Street analysts offering 12 month price targets forVaxcyte Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

Buy

Hold

Sell

Based on 7 analysts giving stock ratings to Vaxcyte Inc - Dist in the past 3 months.

Sentiment

By Acuity

171 / 340 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Vaxcyte Inc

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.